Tonix Pharmaceuticals Holding Corp TNXP shares are trading lower by 17% to $0.49 Wednesday morning. The company late Tuesday announced the topline results of a Phase 2 study for TNX-601 ER, a treatment for major depressive disorder (MDD).
What Happened?
The study did not show significant clinical or statistical improvement in depression severity, as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS) total score. Consequently, the development of TNX-601 ER is being discontinued.
The company says it is now looking forward to receiving topline results from a Phase 2 study of TNX-1900 for chronic migraine in early December and topline results from a Phase 3 study of TNX-102 SL for fibromyalgia in late December.
Tonix says TNX-601 ER was generally well-tolerated, with only a few adverse events reported in the study.
According to data from Benzinga Pro, TNXP has a 52-week high of $9.81 and a 52-week low of $0.46.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
